Obermatt

Clinuvel Pharmaceuticals

ASX:CUV · AU000000CUV3
BiotechnologySmall

360

93
Profit price6
Owner Earnings Yield96
Dividend Yield73
Price/Sales42
EV / Gross Profit53
Price/Book69
Return on Capital93
Cash Return on Capital95
Return on Equity96
EBIT Margin100
Gross Profitability85
Accruals31
Owner Earnings Margin97
Sales growth18
Profit growth40
Reinvestment96
Price momentum43
Debt load95
Refinancing25
Debt Payback100
Liquidity62
Analyst ratings94
Opinion Changes50
Price Target Upside67
Market mood85
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Clinuvel Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryAustralia
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeASX
Founded1999
Employees84
ISINAU000000CUV3
Last UpdateApr 2, 2026
Themes
NeurologyGeneticsDermatologyEndocrinologyGenetic DisorderBiotechnologyDeveloper PlatformPharmaceutical

Description

Clinuvel Pharmaceuticals Limited,engages in the developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders. Business Segments The company operates within a singular operating segment, fo…

Analysis

Quality compounder

Clinuvel Pharmaceuticals Limited is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is attractive. You pay 14.4× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
96
2026

All-time high

96

Jun 2026

All-time low

91

Mar 2026

Average rank

94

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
42
Price/Earnings
73
Price/Book
69
Dividend Yield
73
Value (overall)
85

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Clinuvel Pharmaceuticals with its peers
Jyong Biotech
NMQ:MENS
CountryTaiwan
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Belite Bio
NAQ:BLTE
49
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Zai Lab
HKG:9688
32
CountryChina
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mesoblast
ASX:MSB
42
CountryAustralia
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
J. B. Chemicals & Pharmaceuticals
NSI:JBCHEPHARM
69
CountrySingapore
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Dong-A ST
KSC:170900
39
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →